Abstract 34P
Background
Androgen receptor-positive breast cancer, characterized by overexpression of androgen receptors (ARs), is attracting attention as a subcategory of triple-negative breast cancer (TNBC). The involvement of androgen signaling and the presence of endocrine activity in these TNBC cells make them potential treatment targets. Recent improvements in metabolomics measurement techniques have also revealed the metabolic characteristics of cancer cells. Different cancer cell subtypes exhibit different metabolic balances, and it is believed that a shift to aerobic glycolysis occurs in TNBC, although oxidative phosphorylation has been heavily implicated in endocrine-dependent breast cancer. In this study, we used metabolomics to investigate metabolic regulatory mechanisms in androgen receptor-positive TNBC.
Methods
We introduced ARs into the MDA-MB-231 strain of TNBC cells by using the pEGFP-C1-AR plasmid vector, establishing a stable AR-forced expression TNBC line (MDA-MB-231-AR). Positively ionized metabolites were purified from the parental cell line and the AR forced expression cell line. Metabolome analysis was conducted using a capillary electrophoresis–mass spectrometer (CE-TOFMS/-QqQMS). Data analysis was carried out by extracting, cross-checking, and ordering peaks using MasterHands.
Results
Hierarchical clustering analysis of metabolite peak values showed that the MDA-MB-231-AR strain had improved biological malignancy compared to the parental strain. An evaluation of energy metabolism pathways (the glycolysis system, the pentose phosphate pathway, and tricarboxylic acid cycle) showed that the MDA-MB-231-AR strain had a higher NADH/NAD+ ratio and a lower lactic acid/pyruvic acid ratio than the parental strain, suggesting improved hypoxic metabolism. The glutathione/oxidized glutathione ratio was also lower in the MDA-MB-231-AR cell line than in the parental strain, indicating release from oxidative stress.
Conclusions
Improved hypoxic metabolism was observed in the energy metabolism pathways of AR-positive TNBC cells. This suggests a possible shift from aerobic glycolysis to oxidative phosphorylation might in TNBC cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Impact of chemotherapy and radiotherapy on tissue expander or implant removal in breast cancer patients
Presenter: Sungmi Jung
Session: Poster display session
Resources:
Abstract
5P - Long-term prognostic effect of hormone receptor subtype on breast cancer
Presenter: Ki-tae Hwang
Session: Poster display session
Resources:
Abstract
6P - Effect of apparent diffusion coefficient in predicting pathologic responses in patients with breast cancer treated with neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel
Presenter: Yutaka Mizuno
Session: Poster display session
Resources:
Abstract
7P - Current diagnostic strategy for mammographic microcalcification without specific ultrasound abnormality
Presenter: Naoki Sato
Session: Poster display session
Resources:
Abstract
8P - Comparison of standard uptake value of 18F-FDG-PET-CT with tumour-infiltrating lymphocytes in breast cancer ≥1cm
Presenter: Soeun Park
Session: Poster display session
Resources:
Abstract
10P - Prognosis and effect of adjuvant treatment in small, node(-), HER2(+) breast cancer
Presenter: Seungtaek Lim
Session: Poster display session
Resources:
Abstract
11P - The prognosis of rare histopathologic subtype of breast cancer
Presenter: Soo Youn Bae
Session: Poster display session
Resources:
Abstract
12P - Daily collection of physical activity via smartphone application and smart band for development of distress screening tools in breast cancer survivors: A feasibility study
Presenter: Yungil Shin
Session: Poster display session
Resources:
Abstract
13P - Breast cancer distribution in East Azerbaijan, Iran: Results of population-based cancer registry
Presenter: Shima Pashaei
Session: Poster display session
Resources:
Abstract
14P - Validation of the optimum timing of assessment of tumour infiltrating lymphocytes during preoperative chemotherapy for breast cancer
Presenter: Shinichiro Kashiwagi
Session: Poster display session
Resources:
Abstract